Major Indian Generics Go For Ensured Revenue Rather Than U.S. Patent Courts (India)
This article was originally published in PharmAsia News
Executive Summary
Major Indian Generics Go For Ensured Revenue Rather Than U.S. Patent Courts (India) Major Indian pharmaceutical companies tend to accept out-of-court settlements of patent suits because they realize they need a continuous revenue flow from business abroad. Ranbaxy Laboratories, Dr. Reddy's, Lupin, Ranbaxy, Sun Pharma and Wockhardt have reached settlements by suing U.S. drug makers where in the past they might have pressed their claims in court. Each of the settled cases has involved a deal to be announced later guaranteeing a continued flow of income through the U.S. maker. Industry experts say those agreements are a sign generics makers are becoming more mature. (Click here for more )
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.